Queten Research Institute
Letter data
- Company
- Queten Research Institute
- Recipient
- Jill Seropian | VP | Queten Research Institute | 10 Bloomfield Ave. | Pine Brook | , | NJ | 07058 | United States
- Issue date
- 2021-06-28
- Posted date
- Not available
- FDA office
- Division of Human and Animal Food Operations East II
- Subject
- Not available
- Product
- Food & Beverages
- CMS ID
- 610021
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Queten Research Institute
MARCS-CMS 610021 —
June 28, 2021
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
Via Email
Product:
Food & Beverages
Recipient:
Recipient Name
Jill Seropian
Recipient Title
VP
Queten Research Institute
10 Bloomfield Ave.
Pine Brook
,
NJ
07058
United States
Issuing Office:
Division of Human and Animal Food Operations East II
United States
Dear Ms. Seropian:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter issued to Queten Research Institute on November 5, 2020. Based on our evaluation, it appears that your firm has adequately addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Andrew Ciaccia
Compliance Officer
Human and Animal Food East, Division II
Content current as of:
07/02/2021
Regulated Product(s)
Food & Beverages